MRK Stock Recent News
MRK LATEST HEADLINES
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025.
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
Merck's Q2 2025 results highlight strong growth in Keytruda and Animal Health, while its bullish chart pattern and low valuation make it a compelling long-term buy.
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.
Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 2025 Wells Fargo Healthcare Conference.
Summit Therapeutics Inc SMMT and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.
The Investment Committee debate the latest Calls of the Day.
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--HERTHENA-Breast04 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic HR+/HER2- Breast Cancer.